CN108472385A - 与钉合或拼接肽缀合的生物活性化合物 - Google Patents

与钉合或拼接肽缀合的生物活性化合物 Download PDF

Info

Publication number
CN108472385A
CN108472385A CN201680073127.3A CN201680073127A CN108472385A CN 108472385 A CN108472385 A CN 108472385A CN 201680073127 A CN201680073127 A CN 201680073127A CN 108472385 A CN108472385 A CN 108472385A
Authority
CN
China
Prior art keywords
dccpm
pmo
bac
peptide
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680073127.3A
Other languages
English (en)
Chinese (zh)
Inventor
基思·福斯特
沃特·艾勒斯
亚当·詹姆斯·雷金纳德·加德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sutura Medical Ltd
Original Assignee
Sutura Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutura Medical Ltd filed Critical Sutura Medical Ltd
Publication of CN108472385A publication Critical patent/CN108472385A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
CN201680073127.3A 2015-12-21 2016-12-21 与钉合或拼接肽缀合的生物活性化合物 Pending CN108472385A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1522548.5 2015-12-21
GB1522548.5A GB2545898B (en) 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
PCT/GB2016/054028 WO2017109494A1 (en) 2015-12-21 2016-12-21 Biologically active compound conjugated to a stapled or stitched peptide

Publications (1)

Publication Number Publication Date
CN108472385A true CN108472385A (zh) 2018-08-31

Family

ID=55311362

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073127.3A Pending CN108472385A (zh) 2015-12-21 2016-12-21 与钉合或拼接肽缀合的生物活性化合物

Country Status (10)

Country Link
US (2) US11541124B2 (enExample)
EP (1) EP3393520A1 (enExample)
JP (2) JP2019508481A (enExample)
KR (1) KR20180091920A (enExample)
CN (1) CN108472385A (enExample)
AU (1) AU2016375869B2 (enExample)
BR (1) BR112018012641A2 (enExample)
CA (1) CA3007910A1 (enExample)
GB (1) GB2545898B (enExample)
WO (1) WO2017109494A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
SG10202107429WA (en) 2017-01-06 2021-08-30 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
CA3078504A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CN111447941B (zh) 2017-10-27 2023-10-31 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
US11793884B2 (en) 2018-01-29 2023-10-24 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of CAL-PDZ binding domain
EP3749678A1 (en) * 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
WO2020047399A1 (en) * 2018-08-31 2020-03-05 Massachusetts Institute Of Technology Ionizable lipidoids and their uses
AU2020258482B2 (en) * 2019-04-18 2026-02-12 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like E1-activating enzymes by structurally-stabilized peptides
KR102544364B1 (ko) * 2019-06-17 2023-06-19 주식회사 안단테에프엠 Romo1 유래 항균 펩타이드 및 그 변이체
KR102521182B1 (ko) * 2020-11-06 2023-04-12 서울대학교산학협력단 결핵균 독소-항독소 시스템을 표적으로 하는 항균 스테이플 펩타이드 및 이의 용도
WO2024069229A2 (en) 2022-08-03 2024-04-04 Sutura Therapeutics Ltd Biologically active compounds
WO2025027389A1 (en) 2023-08-03 2025-02-06 Sutura Therapeutics Limited Biologically active compounds comprising a stapled or stitched peptide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101790385A (zh) * 2007-07-12 2010-07-28 普罗森那技术公司 用于使化合物靶向多种选定器官、组织或肿瘤细胞的分子
CN103121959A (zh) * 2011-11-21 2013-05-29 昆山市工业技术研究院小核酸生物技术研究所有限责任公司 化合物和核酸复合分子与核酸复合物及其制备方法和应用
WO2013150338A1 (en) * 2012-04-04 2013-10-10 Centre National De La Recherche Scientifique Stapled cell penetrating peptides for intracellular delivery of molecules
CN103626850A (zh) * 2013-04-03 2014-03-12 安徽省新星药物开发有限责任公司 具有细胞穿透功能的多肽及其在药物递送中的用途
CN103998458A (zh) * 2011-08-30 2014-08-20 医学研究理事会 具有中央疏水域的细胞穿透肽

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972779A3 (en) * 1987-10-28 2004-10-20 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
DK2203173T3 (en) * 2007-10-26 2016-02-29 Academisch Ziekenhuis Leiden Materials and methods for prevention of muscle diseases
US20110250685A1 (en) 2008-06-03 2011-10-13 Nash Huw M Compositions and methods for enhancing cellular transport of biomolecules
EP2762567B1 (en) 2008-10-24 2016-07-13 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
ES2593836T3 (es) * 2009-04-24 2016-12-13 Biomarin Technologies B.V. Oligonucleótido que comprende una inosina para tratar la DMD
US9163330B2 (en) * 2009-07-13 2015-10-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
WO2011111874A1 (ja) 2010-03-11 2011-09-15 独立行政法人理化学研究所 細胞膜透過性ダンベル型rnaおよびその製造方法
KR20130103662A (ko) * 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
WO2012150960A1 (en) 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
WO2014053879A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014064258A1 (en) * 2012-10-26 2014-05-01 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to cell types
US10675356B2 (en) 2015-05-19 2020-06-09 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
EA035733B9 (ru) 2015-07-15 2021-01-14 Протагонист Терепьютикс, Инк. Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
GB2563875B (en) 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101790385A (zh) * 2007-07-12 2010-07-28 普罗森那技术公司 用于使化合物靶向多种选定器官、组织或肿瘤细胞的分子
CN103998458A (zh) * 2011-08-30 2014-08-20 医学研究理事会 具有中央疏水域的细胞穿透肽
CN103121959A (zh) * 2011-11-21 2013-05-29 昆山市工业技术研究院小核酸生物技术研究所有限责任公司 化合物和核酸复合分子与核酸复合物及其制备方法和应用
WO2013150338A1 (en) * 2012-04-04 2013-10-10 Centre National De La Recherche Scientifique Stapled cell penetrating peptides for intracellular delivery of molecules
CN103626850A (zh) * 2013-04-03 2014-03-12 安徽省新星药物开发有限责任公司 具有细胞穿透功能的多肽及其在药物递送中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
杨铭: "3.连接臂link的选择", 《药物研究中的分子识别》 *
王晓良: "二、订书肽的功能与应用", 《应用分子药理学》 *

Also Published As

Publication number Publication date
US20200353092A1 (en) 2020-11-12
US11541124B2 (en) 2023-01-03
AU2016375869B2 (en) 2023-07-13
US20230158166A1 (en) 2023-05-25
CA3007910A1 (en) 2017-06-29
US11944688B2 (en) 2024-04-02
JP2023055874A (ja) 2023-04-18
GB2545898A (en) 2017-07-05
EP3393520A1 (en) 2018-10-31
BR112018012641A2 (pt) 2018-12-04
WO2017109494A1 (en) 2017-06-29
JP2019508481A (ja) 2019-03-28
AU2016375869A1 (en) 2018-08-09
GB201522548D0 (en) 2016-02-03
GB2545898B (en) 2019-10-09
KR20180091920A (ko) 2018-08-16

Similar Documents

Publication Publication Date Title
US11944688B2 (en) Biologically active compounds
JP4974890B2 (ja) ペプチドが結合された、イノシン置換アンチセンスオリゴマー化合物および方法
CN103998458B (zh) 具有中央疏水域的细胞穿透肽
WO2021127650A1 (en) Compositions for delivery of antisense compounds
JP5635512B2 (ja) 遺伝子調節化合物の改良された送達のための化学的に修飾された細胞透過性ペプチド
US20110105403A1 (en) Peptides
JP2023126866A (ja) 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物
WO2023026994A1 (ja) ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
CN117285626A (zh) αvβ6整联蛋白配体及其应用
KR102890965B1 (ko) 세포 투과 펩티드
JPWO2017109494A5 (enExample)
WO2008043366A2 (en) Three-domain compounds for transmembrane delivery
JPWO2019002875A5 (enExample)
WO2024069229A2 (en) Biologically active compounds
GB2574525A (en) Improvements in drug delivery
GB2580569A (en) Improvements in drug delivery
Li et al. Emerging Landscape of Therapeutic Oligonucleotide Delivery by Cell‐penetrating Peptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180831